anti-CD7 universal CAR-T cells

Anti-CD7 universal CAR-T cells are genetically engineered allogeneic T cells expressing a chimeric antigen receptor (CAR) that targets CD7, a cell surface antigen highly expressed in T-cell leukemias and lymphomas. These cells are made "universal" or "off-the-shelf" by using gene editing (commonly CRISPR or other genome engineering platforms) to knock out endogenous T cell receptor (TCR, to reduce risk of graft-versus-host disease) and CD7 itself (to avoid fratricide among CAR-T cells), and sometimes with additional engineering to reduce rejection and prolong persistence. Some advanced versions (e.g., RD13-02) include further molecular modifications to reduce host NK and T cell-mediated rejection. These products are in clinical development, primarily for relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL), T-cell lymphoblastic lymphoma (T-LBL), and other CD7-positive T/NK cell malignancies[1][2][3][4][5][6][8][9].

Other names

universal anti-CD7 CAR-T cellsoff-the-shelf anti-CD7 CAR-T cellsanti-CD7 U-CAR-T cellsanti-CD-7 U-CAR-T cellsanti-CD 7 U-CAR-T cells